Gliclazide

Structural formula
General
Surname	Gliclazide
other names	1- (3-Azabicyclo [3.3.0] oct-3-yl) -3- p -tolylsulfonylurea; 1- (Hexahydrocyclopenta [ c ] pyrrol-2-yl) -3- ( p -tolylsulfonyl) urea;
Molecular formula	C 15 H 21 N 3 O 3 S
External identifiers / databases
EC number	244-260-5
ECHA InfoCard	100.040.221
PubChem	3475
DrugBank	DB01120
Wikidata	Q290001
Drug information
ATC code	A10 BB09
Drug class	Sulfonylureas
Mechanism of action	Potassium channel blockers
properties
Molar mass	323.41 g mol −1
Physical state	firmly
Melting point	163-169 ° C ; 180-182 ° C;
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances	no GHS pictograms
	no GHS pictograms
H and P phrases	H: no H-phrases
	P: no P-phrases
Toxicological data	3000 mg kg −1 ( LD 50 , rat , oral ) ; 382 mg kg −1 ( LD 50 , rat , iv ) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Gliclazid (trade name Diamicron UNO ) is a chemical compound from the group of sulfonylureas that is used to treat diabetes mellitus . The oral antidiabetic was patented by Science Union and is now available from Servier .

Clinical information

Application areas (indications)

Gliclazid is indicated for non-insulin-dependent type 2 diabetes mellitus, when diet, physical activity and weight loss are insufficient to control blood sugar. A combination with other antidiabetic agents is also possible.

Contraindications (contraindications)

Gliclazide is contraindicated in severe renal insufficiency and severe hepatic insufficiency. In these cases, the use of insulin is recommended.
As a sulfonamide, a cross allergy with other sulfonamides must be assumed, which is why it should not be used in a known allergy.

literature

G. Bardini, E. Mannucci, CM Rotella: Effect of different pharmacological formulations of gliclazide on postprandial hyperglycaemia. In: Diabetic medicine: a journal of the British Diabetic Association. Volume 15, Number 8, August 1998, p. 706, PMID 9702477 ( PDF ).
Richard Daikeler, Götz Use, Sylke Waibel: Diabetes. Evidence-based diagnosis and therapy. 10th edition. Kitteltaschenbuch, Sinsheim 2015, ISBN 978-3-00-050903-2 , p. 168 f.

Individual evidence

↑ ^a ^b Datasheet Gliclazide, European Pharmacopoeia (EP) Reference Standard from Sigma-Aldrich , accessed on October 20, 2016 ( PDF ).
↑ ^a ^b ^c ^d Entry on gliclazide. In: Römpp Online . Georg Thieme Verlag, accessed on 2014-10-28.

[Sigma-1] Datasheet Gliclazide, European Pharmacopoeia (EP) Reference Standard from Sigma-Aldrich , accessed on October 20, 2016 ( PDF ).

[roempp-2] Entry on gliclazide. In: Römpp Online . Georg Thieme Verlag, accessed on 2014-10-28.